Sapna P Patel is Assistant Professor and Director of Online Media in the Department of Melanoma Medical Oncology at the MD Anderson Cancer Center (TX, USA). She is Lead Physician for uveal melanoma trials at the MD Anderson Cancer Center, and is collaborating to develop other strategies and clinical trials for uveal melanoma patients utilizing immunotherapy, targeted therapy and adjuvant therapy.

Dan S Gombosis a full-time Ocular Oncologist and Chief of Ophthalmology at the MD Anderson Cancer Center, with a focus on ocular melanoma and retinoblastoma. He is Clinical Co-Director of the Retinoblastoma Center of Houston (TX, USA), with joint appointments at Texas Children’s Hospital (USA), Baylor College of Medicine (TX, USA) and the Methodist Research Institute (TX, USA).

Search for more papers by this author

Published Online:9 Jul 2014https://doi.org/10.2217/fmeb2013.13.35

View chapter

Abstract:

Nearly 50% of patients with ocular melanoma will develop distant metastasis. Adjuvant therapy, which has been shown to be of benefit in other solid tumors, may have similar applications in this neoplasm. This chapter will review methods of tumor prognostication and consider treatment strategies for high-risk patients. Chemotherapy, immune modulation and liver-directed therapies will be reviewed. Finally, approaches for adjuvant trial design will be discussed.

References

1
Early Breast Cancer Trialists‘ Collaborative Group
. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet 365 (9472) , 1687 – 1717 (2005) .
MedlineGoogle Scholar
2 Cuzick J , Sestak I , Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial . Lancet Oncol. 11 (12) , 1135 – 1141 (2010) .
Medline CASGoogle Scholar
3 Martin M , Villar A , Sole-Calvo A et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer:
a study by the GEICAM Group
. Ann. Oncol. 14 (6) , 833 – 842 (2003) .
Medline CASGoogle Scholar
4 Slamon D , Eiermann W , Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer . N. Engl. J. Med. 365 (14) , 1273 – 1283 (2011) .
Medline CASGoogle Scholar
5 Arriagada R , Dunant A , Pignon JP et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer . J. Clin. Oncol. 28 (1) , 35 – 42 (2010) .
Medline CASGoogle Scholar
6 Tournigand C , Andre T , Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study . J. Clin. Oncol. 22 (2) , 229 – 237 (2004) .
Medline CASGoogle Scholar
7 Kirkwood JM , Strawderman MH , Ernstoff MS , Smith TJ , Borden EC , Blum RH . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 . J. Clin. Oncol. 14 (1) , 7 – 17 (1996) .
Medline CASGoogle Scholar
8 Singh AD , Shields CL , Shields JA . Prognostic factors in uveal melanoma . Melanoma Res. 11 (3) , 255 – 263 (2001) .
Medline CASGoogle Scholar
9 Shields CL , Furuta M , Thangappan A et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes . Arch. Ophthalmol. 127 (8) , 989 – 998 (2009) .
MedlineGoogle Scholar
10 Shields CL , Ganguly A , Bianciotto CG , Turaka K , Tavallali A , Shields JA . Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens . Ophthalmology 118 (2) , 396 – 401 (2011) .
MedlineGoogle Scholar
11 Onken MD , Worley LA , Tuscan MD , Harbour JW . An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma . J. Mol. Diagn. 12 (4) , 461 – 468 (2010) .
Medline CASGoogle Scholar
12 Lane AM , Egan KM , Harmon D , Holbrook A , Munzenrider JE , Gragoudas ES . Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis . Ophthalmology 116 (11) , 2206 – 2212 (2009) .
MedlineGoogle Scholar
13 Desjardins L DT , Levy Al CE . Randomized study on adjuvant therapy by DTIC in choroidal melanoma . Ophthalmologie 12 , 168 – 173 (1998) .
Google Scholar
14 Voelter V , Schalenbourg A , Pampallona S et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients . Melanoma Res. 18 (3) , 220 – 224 (2008) .
Medline CASGoogle Scholar
15 Mallikarjuna K , Pushparaj V , Biswas J , Krishnakumar S . Expression of insulin-like growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: an immunohistochemical study . Curr. Eye Res. 31 (10) , 875 – 883 (2006) .
MedlineGoogle Scholar
16 Ma D , Niederkorn JY . Role of epidermal growth factor receptor in the metastasis of intraocular melanomas . Invest. Ophthalmol. Vis. Sci. 39 (7) , 1067 – 1075 (1998) .
Medline CASGoogle Scholar
17 Landreville S , Agapova OA , Matatall KA et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma . Clin. Cancer Res. 18 (2) , 408 – 416 (2012) .
Medline CASGoogle Scholar

Website

101 ClinicalTrials.gov. http://clinicaltrials.gov
Google Scholar

Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies

Metrics

Downloaded 3 times

History

Published online 9 July 2014

Published in print July 2014

Information

PDF download

Adjunctive treatment strategies for high-risk ocular melanoma

References

Website